|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||20.07 / 39.17|
Investors eyeing a purchase of Repligen Corp. stock, but cautious about paying the going market price of $26.29/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Record quarterly revenue of $25.1 million, reflecting 21% year-over-year growth
Webcast and Conference Call to Be Held Thursday, May 5, 8:30 a.m. ET
Broadens portfolio, expands customer base and increases capabilities in growing pre-packed chromatography column market
Recognized Experts in Bioprocessing to Provide Input on Product Innovation and Portfolio Expansion for Repligen
I have a plethora of indicators that say we should get some sort of correction.
- Reaffirms Position as Strategic Supplier of Affinity Ligands to GE Healthcare -
Webcast and Conference Call to be Held Thursday, February 25, 8:30 a.m. ET
Investors eyeing a purchase of Repligen Corp. shares, but cautious about paying the going market price of $22.29/share, might benefit from considering selling puts among the alternative strategies at their disposal.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCR, DCUB, DVD, KLAC, QLGC Downgrades: ABG, AKAM, ATTU, BIO, BMY, BOKF, CHH, FFIV, HMC, HUBB, LLL, LRN, MJN, MLI, OSIS, RGEN, SCS, SP, TRN, URI, VLY, WERN, ZION Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 571,244 share decrease in total short interest for Repligen Corp. , to 1,749,140, a decrease of 24.62% since 12/15/2015.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Repligen Corp. saw new options begin trading this week, for the December 18th expiration.
Trade-Ideas LLC identified Repligen (RGEN) as a weak on high relative volume candidate
- Webcast and Conference Call to be Held Thursday, November 5, 8:30 a.m. ET -
- Webcast and Conference Call to be Held Thursday, November 6, 8:30 a.m. ET -
The most recent short interest data has been released by the NASDAQ for the 07/31/2015 settlement date, which shows a 392,926 share decrease in total short interest for Repligen Corp. , to 3,056,959, a decrease of 11.39% since 07/15/2015.
Webcast and Conference Call to be Held Thursday, August 6, 8:30 a.m. ET
Trade-Ideas LLC identified Repligen (RGEN) as a "dead cat bounce" (down big yesterday but up big today) candidate